BioCorRx awarded $3.5M NIDA grant for first-in-human trial of BICX104 implant

BioCorRx Inc.

Award of ~$3.5M from NIDA for second phase (UH3) of grant; total NIDA funding now ~$5.7M.
Funding supports first-in-human clinical trial of BICX104, an implantable naltrexone pellet for opioid use disorder.
Company previously received FDA clearance to proceed to human trials; aims to begin trial in 2021.
Grant is non-dilutive, covering substantial costs toward FDA approval for BICX104.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.